Lastly, Cumbo et al. reported a study of MRD monitoring in CML with a DNA-based assay to enhance the sensitivity of detection of BCR-ABL1 positive cells, in detecting the BCR-ABL1 genomic rearrangement. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.